Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Inventiva
  6. News
  7. Summary
    IVA   FR0013233012

INVENTIVA

(IVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Inventiva to host a webcast with Key Opinion Leaders from the AASLD The Liver Meeting™ 2021

11/03/2021 | 03:05pm EST

Daix (France), Long Island City (New York, United States), November 3, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical needs, today announced that it will host a webcast event focused on NASH with the participation of four Key Opinion Leaders (KOLs) on November 19, 2021 from The Liver Meeting™ 2021, organized by the American Association for the Study of Liver Diseases (AASLD).

Following an introduction from Frédéric Cren, Chairman, CEO and cofounder of Inventiva and Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, the event will consist of the presentation of five scientific abstracts presented at AASLD The Liver Meeting™ 2021, as well as four presentations focused on the latest news around the development of lanifibranor and various aspects related to NASH. As part of the program, there will be dedicated Q&A sessions.

Download PDF

Disclaimer

Inventiva SA published this content on 03 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 November 2021 20:04:18 UTC.


ę Publicnow 2021
All news about INVENTIVA
01/14INVENTIVA : to present at the 40th Annual J.P. Morgan Healthcare Conference
PU
01/14Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
AQ
01/06INVENTIVA : Corporate Presentation January 2021
PU
2021INVENTIVA : Monthly statement on outstanding equity shares and voting rights
CO
2021Inventiva to present at the 40th Annual J.P. Morgan Healthcare Conference
AQ
2021Inventiva Confirms Safety of Liver Disease Drug in Clinical Trial Measuring Cardiac Ele..
MT
2021INVENTIVA : announces positive results of clinical thorough QT study conducted with lanifi..
PU
2021Inventiva announces positive results of clinical thorough QT study conducted with lanif..
AQ
2021Inventiva Announces Positive Results of Clinical Thorough QT Study Conducted with Lanif..
CI
2021INVENTIVA : Corporate Presentation December 2021
PU
More news
Analyst Recommendations on INVENTIVA
More recommendations
Financials
Sales 2021 5,07 M 5,74 M 5,74 M
Net income 2021 -51,6 M -58,5 M -58,5 M
Net cash 2021 47,3 M 53,6 M 53,6 M
P/E ratio 2021 -9,12x
Yield 2021 -
Capitalization 449 M 509 M 509 M
EV / Sales 2021 79,4x
EV / Sales 2022 10,9x
Nbr of Employees 100
Free-Float 78,3%
Chart INVENTIVA
Duration : Period :
Inventiva Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 11,00 €
Average target price 27,23 €
Spread / Average Target 148%
EPS Revisions
Managers and Directors
FrÚdÚric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial & Administrative Officer
Pierre Broqua Director, Deputy CEO & Chief Scientific Officer
Michael P. Cooreman Chief Medical Officer
Alice Roudot-Ketelers Vice President-Clinical Operations
Sector and Competitors
1st jan.Capi. (M$)
INVENTIVA-6.30%509
GILEAD SCIENCES, INC.-3.00%88 346
REGENERON PHARMACEUTICALS-3.21%63 906
VERTEX PHARMACEUTICALS5.22%58 750
WUXI APPTEC CO., LTD.-0.66%54 178
BIONTECH SE-34.36%40 873